Global Meloxicam Market Size study, by Diseases (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Others) by Drug Type (Generic, Branded) by Population Type (Adult, Children) by Dosage (Oral, Parenteral, transdermal, Others) by Dose St

Global Meloxicam Market Size study, by Diseases (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Others) by Drug Type (Generic, Branded) by Population Type (Adult, Children) by Dosage (Oral, Parenteral, transdermal, Others) by Dose Strength (7.5mg, 15mg, Others) by End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others) by Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) and Regional Forecasts 2022-2028Global Meloxicam Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Meloxicam is a type of drug which is used to treat the pain and inflammation in rheumatic diseases and osteoarthritis. The increasing geriatric population and developmental strategies between hospitals has led the adoption of Meloxicam across the forecast period. For Instance: as per the Statistics Netherlands’ population, in 2019 there was half the Dutch adult population was older than 50 years which will rise the meloxicam market. So, there is nearly 14 million adults and 7 million people over 50s. Also, with the rising prevalence of chronic inflammatory and pain diseases, the adoption & demand for Meloxicam is likely to increase the market growth during the forecast period. However, rising preference of NSAIDs over other pain killers impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Meloxicam market study includes Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the dominating region across the world in terms of market share owing to the presence of rising population with arthritis & other chronic pain diseases, high healthcare expenditure and research & development. Whereas, Asia-Pacific is anticipated to exhibit highest growth rate over the forecast period 2022-2028. Factors such as increased advancement in the technology as well as growing healthcare expenditure and rising awareness program would create lucrative growth prospects for the Meloxicam market across Asia-Pacific region.

Major market player included in this report are:
Taj Pharmaceutical Limited.
Wellona Pharma
Trumac Healthcare
Healthy Life Pharma Private Limited.
EPICON LIFESCIENCES LLP
Boehringer Ingelheim GmbH.
Baudax Bio
Viatris Inc.
Avanstra Inc.
PD-Rx Pharmaceuticals, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Diseases:
Osteoarthritis
Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Others
By Drug Type:
Generic
Branded
By Population Type:
Adult
Children
By Dosage:
Oral
Parenteral
transdermal
Others
By Dose Strength:
7.5mg
15mg
Others
By End-Users:
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel:
Direct Tender
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Meloxicam Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Taj Pharmaceutical Limited.
Wellona Pharma
Trumac Healthcare
Healthy Life Pharma Private Limited.
EPICON LIFESCIENCES LLP
Boehringer Ingelheim GmbH.
Baudax Bio
Viatris Inc.
Avanstra Inc.
PD-Rx Pharmaceuticals, Inc.